Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who are able to give written consent and follow the study requirements for the full duration of the trial
• People who have been diagnosed with type 1 or type 2 diabetes, supported by lab results, or current regular use of insulin or oral diabetes medications
• People who have retinal swelling caused by fluid in the central part of the macula (the central area of the eye used for detailed vision), which may be associated with diabetic eye disease
• People whose eye scans (OCT) and clinical examination confirm diabetic macular edema in the center of the macula, with a central thickness measurement greater than 300 microns
• People whose vision in the study eye falls within a specific range — roughly between 20/400 and 20/40 on an eye chart
• People whose eyes are clear enough and whose pupils can dilate sufficiently to allow eye scans and retinal photography
• People who are willing and able to attend all scheduled visits and assessments

Who may not be able to join:

• People who have received an injection into the study eye (such as Bevacizumab or Ranibizumab), verteporfin, or photodynamic therapy within the past 3 months (certain laser treatments outside the central retina may be acceptable — confirm with trial site)
• People who have had laser treatment to the study eye within the past 1 month
• People currently taking part in another eye-related clinical trial or investigation
• People who are pregnant, have tested positive for pregnancy, or pre-menopausal women not using adequate contraception
• People with significantly high blood pressure (above 160/100 mmHg), a blood sugar reading at or above 12 mmol/L, or a long-term blood sugar marker (HbA1c) at or above 7.5%
• People whose macular swelling appears to be caused by a structural problem at the back of the eye or a disease of the optic nerve, as identified by examination or eye scan
• People who have another eye condition in the study eye that may need treatment during the study, or that could cause vision loss (for example, an advanced cataract, uncontrolled glaucoma, eye inflammation, or a previous corneal transplant) — the trial investigator will make this assessment
• People whose study eye, in the investigator's opinion, has no realistic chance of vision improvement even if the macular swelling resolves (for example, due to scarring or tissue loss at the back of the eye)
• People with a suspected active infection in or around the eye, or another eye condition that could affect vision or macular swelling during the study
• People with bleeding inside the eye (vitreous hemorrhage) that blocks the view of the retina
• People who have had eye surgery — including vitreous surgery, cataract surgery, or a specific laser capsule procedure (YAG capsulotomy) — in the study eye within the past 3 months
• People whose other (non-study) eye has vision worse than 20/400
• People with a known allergy or sensitivity to Ranibizumab or any ingredient in the study medication
• People who have had a stroke or heart attack within the past 3 months
• Staff employed at the trial site, people directly involved in running the study, their immediate family members, prisoners, or people who are legally institutionalised
• People currently taking certain medications known to be harmful to the eye's lens, retina, or optic nerve — including deferoxamine, chloroquine, hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin, or ethambutol — and these medications would not be permitted during the study either

Important: Always verify eligibility with the trial site directly before applying.